The HYDRASHIFT portfolio include IVD test to mitigate interferences seen in immunofixation result for patient treated with isatuximab or daratumumab.
Knowledge & Science
Results
The serum Free Light Chains is an important test in Prognosis and Monitoring of Multiple Myeloma patients.
